2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCoated Materials, BiocompatibleDrug-Eluting StentsFemoral ArteryHumansMedicarePeripheral Arterial DiseasePopliteal ArteryTreatment OutcomeUnited StatesConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCoated Materials, BiocompatibleFemoral ArteryHumansPeripheral Arterial DiseasePopliteal ArteryStentsTreatment OutcomeVascular Patency
2022
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCoated Materials, BiocompatibleDrug-Eluting StentsFemaleFemoral ArteryHumansMedicarePeripheral Arterial DiseasePopliteal ArteryTreatment OutcomeUnited StatesVascular PatencyConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classification